



Figure * \$ | A-D Albert et al.







a









Figure 1, Albert et al.



















В
















CD4 helper cells 'license' the DC to cross-prime via CD40 ligation




· 医髓红色的 是一种。

FK506, but not CsA inhibits cross-priming by affecting the DC



No residual FK506 remains in coculture




with the addition of FK506 during the 36 hour DC-Apoptotic cell coculture. DCs were collected, washed, counted and plated in wells containing purified CD8+ T cells with αCD40 antibody with the addition of supernatant from the FK506 DC-Apoptotic cell coculture to untreated DCs. No residual FK506 remained in the coculture to inhibit T cell activation. Red bars, DCs + infected EL4 cells; White bars, DCs + uninfected EL4 cells.

FK506 ELISPOT FK506 selectively affects the exogenous MHC I pathway Matrix Peptide DMSO Media 200 800 009 400 Spot forming cells/106 cells FK506 DMSO Media + apoptotic cell Spot forming cells/106 cells FK506 $CD8 + \alpha CD40$ Apoptotic Cell DMSO Media Spot forming cells/10 6 cells 2

FIG 11 A-13

FK506 does not inhibit phagocytosis




cocultured with the apoptotic cells. Cocultures were then analyzed by FACS, gating on dendritic cells. Double positive cells were scored as a measure of percent phagocytosis. FK506 does not EL4 cells were dyed with PKH26, UVB irradiated and allowed to undergo apoptosis for 8 hours. Day 6 immature DCs were treated with 0.5µM FK506 for 24 hours, dyed with PKH67 and then inhibit antigen capture.

Immature DCs (PKH67)




FK506 does not inhibit Dendritic Cell maturation



Cultures were established as previously described with the addition of 0.5 µM FK506 during the 36 hour DC-Apoptotic cell coculture. DCs were collected, washed and stained for HLA-DR. HLA-DR⁺ DCs were then gated on to exclude apoptotic debris and analyzed by FACS for their CD14, CD83 and HLA-DR expression. FK506 does not act to inhibit cross-priming by affecting DC maturation.


FK506 does not inhibit generation of MHC I / peptide complex



Influenza Specific CTLs used as effector cells

30.


35





Lysis (%)

DCs cross-presenting apoptotic cells used as targets

5










5:1

15:1


50:1

FK506 acts to inhibit cross-priming by blocking signaling of TNF superfamily members



FK506 treated DCs block signaling of CD40, RANK and OX40 in the Cocultures were established as previously described +/- FK506 treatment. DCs were collected, counted and plated in wells containing purified CD8+ T cells ELISPOT assay was performed and spot forming cells/ 10^6 cells are reported. with 1µg/mL \alpha CD40 antibody (Mabtech), human recombinant RANKL (Kamiya Biomedical), or human recombinant OX40L (Alexis Biochemicals). exogenous pathway.

Assaying for Tolerance vs. Ignorance



FK506 cross-tolerizes antigen specific CD8⁺ T cells

